XOMA Royalty Corporation (XOMA)
| Market Cap | 523.02M +86.3% |
| Revenue (ttm) | 48.56M +13.2% |
| Net Income | 19.93M |
| EPS | 1.58 |
| Shares Out | 12.54M |
| PE Ratio | 26.46 |
| Forward PE | 72.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,505 |
| Open | 41.84 |
| Previous Close | 42.00 |
| Day's Range | 41.55 - 41.89 |
| 52-Week Range | 22.29 - 42.81 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 52.50 (+25.88%) |
| Earnings Date | May 26, 2026 |
About XOMA
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price target is $52.5, which is an increase of 25.88% from the latest price.
News
Xoma downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis downgraded Xoma (XOMA) to Neutral from Buy with a $39 price target citing the pending acquisition by Ligand.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
Ligand price target raised to $255 from $230 at Stifel
Stifel raised the firm’s price target on Ligand (LGND) to $255 from $230 and keeps a Buy rating on the shares after the company agreed to acquire Xoma (XOMA) for…
Xoma downgraded to Neutral from Buy at Lucid Capital
Lucid Capital analyst Elemer Piros downgraded Xoma (XOMA) to Neutral from Buy with a price target of $39, down from $66, after Ligand Pharmaceuticals (LGND) announced a definitive agreement to…
Ligand to acquire Xoma for $39.00 per share in cash
Ligand (LGND) and Xoma (XOMA) announced that the companies have entered into a definitive agreement under which Ligand will acquire Xoma Royalty for $39.00 per share of common stock in…
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por...
Ligand to buy Xoma for $39 per share, WSJ reports
Ligand Pharmaceuticals (LGND) has reached a roughly $740M deal to buy Xoma XOMA Royalty (XOMA) at $39 per share, people familiar with the matter told The Wall Street Journal. The…
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Roy...
XOMA Royalty Earnings Call Transcript: Q4 2025
2025 saw strong financial growth, with royalty receipts up 68% year-over-year and positive operating cash flow enabling $16 million in share buybacks. The portfolio expanded to over 120 assets, with several late-stage catalysts expected in 2026 and a focus on disciplined capital allocation.
Xoma reports Q4 EPS 26c, consensus (13c)
Reports Q4 revenue $13.8M, consensus $11.05M. “We continue to search for innovative ways to drive enhanced optionality in the XOMA (XOMA) portfolio, with the addition of 22 assets and two…
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up ...
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results o...
XOMA Royalty Transcript: Leerink Global Healthcare Conference 2026
Management highlighted a diversified, royalty-driven portfolio strategy, recent creative acquisitions, and ongoing litigation with J&J over Tremfya royalties. Financials show strong cash flow and low tax rates, with multiple late-stage pipeline catalysts expected in 2024 and 2027.
XOMA Royalty Transcript: TD Cowen 46th Annual Health Care Conference
The company has built a diversified royalty portfolio with over 120 assets, including 15 in phase III, and uses creative transactions to drive growth and tax efficiency. Key catalysts include multiple phase III readouts and commercial launches, with profitability expected by 2027. Strategic capital allocation and share buybacks aim to maximize shareholder value.
Xoma price target raised to $50 from $45 at Leerink
Leerink raised the firm’s price target on Xoma (XOMA) to $50 from $45 and keeps an Outperform rating on the shares.
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helpin...
Xoma announces CFO Burns to step down, Trigilio to succeed
XOMA (XOMA) Royalty Corporation announced its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities. In conjunctio...
XOMA Royalty Announces CFO Transition
EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his...
H.C. Wainwright remains bullish on Xoma following creative Takeda deal
H.C. Wainwright says Xoma (XOMA) took “a nice ride down the creativity road again with nice pipeline expansion,” after the company announced an expanded relationship with partner Takeda (TAK). The…
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
XOMA Royalty (XOMA) has amended its collaboration, originally established in 2006, with Takeda (TAK) through a strategic royalty share transaction. Takeda’s royalty and milestone payment obligations t...
Generation Bio price target lowered to $5.50 from $7 at Wedbush
Wedbush lowered the firm’s price target on Generation Bio (GBIO) to $5.50 from $7 and keeps a Neutral rating on the shares. Xoma (XOMA) will acquire Generation Bio for $4.2913/share…
Generation Bio downgraded to Hold from Buy at Jefferies
Jefferies downgraded Generation Bio (GBIO) to Hold from Buy with a price target of $5, down from $11, citing the pending takeover by Xoma (XOMA). Although the $4.29 per share…
Xoma to acquire Generation Bio for $4.2913 per share
17:02 EST Xoma (XOMA) to acquire Generation Bio (GBIO) for $4.2913 per share
Xoma to acquire Generation Bio for $4.2913 per share
Xoma Royalty (XOMA) announced it has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation…
Xoma price target lowered to $97 from $104 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Xoma (XOMA) to $97 from $104 and keeps a Buy rating on the shares after removing ersodetug from the…